Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-21T04:36:54.089Z Has data issue: false hasContentIssue false
  • English
  • Français

P0320 - Polyunsaturated fatty acids and depression: Preliminary results of a randomized double blind placebo controlled study

Published online by Cambridge University Press:  16 April 2020

M. Pomponi ,
S. Lippa ,
R. Natili ,
M. Di Nicola ,
C. Ciciarelli ,
M. Mazza ,
C. Villella ,
S. Andreoli ,
G. Conte  and
L. Janiri
...Show all authors
M. Pomponi
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
S. Lippa
Affiliation:
Institute of Biochemestry and Clinical Biochemestry, Rome, Italy
R. Natili
Affiliation:
Institute of Biochemestry and Clinical Biochemestry, Rome, Italy
M. Di Nicola
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
C. Ciciarelli
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
M. Mazza
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
C. Villella
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
S. Andreoli
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
G. Conte
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
L. Janiri
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy
P. Bria
Affiliation:
Institute of Psychiatry and Clinical Psychology, Rome, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Many scientific articles suppose a role of omega-3 polyunsaturated fatty acids (PUFA) - particularly eicosapentaenoic acid (EPA; 20:5, n-3) and docosahexaenoic acid (DHA; 22:6, n-3) - as an adjuvant therapy of depression.

We are carrying out a randomized double-blind placebo controlled study - approved by Ethic Committee - to evaluate the adjuvant effect of EPA and DHA in the therapy with paroxetine mesylate, a selective serotonin re-uptake inhibitor (SSRI), in unipolar mood depression and recurrent depression.

In the first phase (T0 baseline), the authors enrolled 20 patients, male or female, between 20 and 60 years old, affected by major depression or recurrent depression according to DSM IV TR. We excluded anticoagulant therapies, pregnancy, concomitant treatment with other drugs and presence of psychotic disorders. The initial plasmatic fatty acid level of cohort of 55 subjects (20 patients and 35 controls) has been evaluated by gas chromatography.

Our preliminary results indicate a general alteration of serum fatty acid levels in depressed subjects compared to healthy subjects, with a high significant statistical difference between the two groups. This difference may help in defining a biological indicator of mood depression. A remarkable different serum fatty acid concentration was still observed, after adjustments regarding diet.

Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006 Jun;163(6):969-78.

Type
Poster Session I: Biological Markers
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S175
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.